Literature DB >> 29404570

Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Nisha Bansal1, Adam Szpiro2, Kristi Reynolds3, David H Smith4, David J Magid5, Jerry H Gurwitz6, Frederick Masoudi7, Robert T Greenlee8, Grace H Tabada9, Sue Hee Sung9, Ashveena Dighe1, Alan S Go9,10,11,12.   

Abstract

Importance: Chronic kidney disease (CKD) is common in adults with heart failure and is associated with an increased risk of sudden cardiac death. Randomized trials of participants without CKD have demonstrated that implantable cardioverter defibrillators (ICDs) decrease the risk of arrhythmic death in selected patients with reduced left ventricular ejection fraction (LVEF) heart failure. However, whether ICDs improve clinical outcomes in patients with CKD is not well elucidated. Objective: To examine the association of primary prevention ICDs with risk of death and hospitalization in a community-based population of potentially ICD-eligible patients who had heart failure with reduced LVEF and CKD. Design, Settings, and Participants: This noninterventional cohort study included adults with heart failure and an LVEF of 40% or less and measures of serum creatinine levels available from January 1, 2005, through December 31, 2012, who were enrolled in 4 Kaiser Permanente health care delivery systems. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m2. Patients who received and did not receive an ICD were matched (1:3) on CKD status, age, and high-dimensional propensity score to receive an ICD. Follow-up was completed on December 31, 2013. Data were analyzed from 2015 to 2017. Exposures: Placement of an ICD. Main Outcomes and Measures: All-cause death, hospitalizations due to heart failure, and any-cause hospitalizations.
Results: A total of 5877 matched eligible adults with CKD (1556 with an ICD and 4321 without an ICD) were identified (4049 men [68.9%] and 1828 women [31.1%]; mean [SD] age, 72.9 [8.2] years). In models adjusted for demographics, comorbidity, and cardiovascular medication use, no difference was found in all-cause mortality between patients with CKD in the ICD vs non-ICD groups (adjusted hazard ratio, 0.96; 95% CI, 0.87-1.06). However, ICD placement was associated with increased risk of subsequent hospitalization due to heart failure (adjusted relative risk, 1.49; 95% CI, 1.33-1.60) and any-cause hospitalization (adjusted relative risk, 1.25; 95% CI, 1.20-1.30) among patients with CKD. Conclusions and Relevance: In a large, contemporary, noninterventional study of community-based patients with heart failure and CKD, ICD placement was not significantly associated with improved survival but was associated with increased risk for subsequent hospitalization due to heart failure and all-cause hospitalization. The potential risks and benefits of ICDs should be carefully considered in patients with heart failure and CKD.

Entities:  

Mesh:

Year:  2018        PMID: 29404570      PMCID: PMC5885920          DOI: 10.1001/jamainternmed.2017.8462

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  46 in total

1.  High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Authors:  E Garbe; S Kloss; M Suling; I Pigeot; S Schneeweiss
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

2.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.

Authors:  Fred M Kusumoto; Hugh Calkins; John Boehmer; Alfred E Buxton; Mina K Chung; Michael R Gold; Stefan H Hohnloser; Julia Indik; Richard Lee; Mandeep R Mehra; Venu Menon; Richard L Page; Win-Kuang Shen; David J Slotwiner; Lynne Warner Stevenson; Paul D Varosy; Lisa Welikovitch
Journal:  J Am Coll Cardiol       Date:  2014-05-09       Impact factor: 24.094

5.  An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status.

Authors:  D N Wentworth; J D Neaton; W L Rasmussen
Journal:  Am J Public Health       Date:  1983-11       Impact factor: 9.308

6.  Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.

Authors:  Eric S Williams; Svati H Shah; Jonathan P Piccini; Albert Y Sun; Jason I Koontz; Sana M Al-Khatib; Patrick M Hranitzky
Journal:  Europace       Date:  2011-08-06       Impact factor: 5.214

7.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program.

Authors:  Stephen Sidney; Michael Sorel; Charles P Quesenberry; Cynthia DeLuise; Stephan Lanes; Mark D Eisner
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure.

Authors:  Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz
Journal:  Am Heart J       Date:  2003-08       Impact factor: 4.749

9.  Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation.

Authors:  Atul Aggarwal; Yongfei Wang; John S Rumsfeld; Jeptha P Curtis; Paul A Heidenreich
Journal:  Heart Rhythm       Date:  2009-08-05       Impact factor: 6.343

10.  Effect of renal function on survival after implantable cardioverter defibrillator placement.

Authors:  Casey S Hager; Sunil Jain; Jeffry Blackwell; Benjamin Culp; Juhee Song; Christopher D Chiles
Journal:  Am J Cardiol       Date:  2010-11-01       Impact factor: 2.778

View more
  8 in total

1.  Frailty, Implantable Cardioverter Defibrillators, and Mortality: a Systematic Review.

Authors:  Michael Y Chen; Ariela R Orkaby; Michael A Rosenberg; Jane A Driver
Journal:  J Gen Intern Med       Date:  2019-07-01       Impact factor: 5.128

2.  Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: A Focus on Heart Failure.

Authors:  Nisha Bansal
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-15       Impact factor: 8.237

Review 3.  Updates in the management of heart failure for the chronic kidney disease patient.

Authors:  Simon Hsu; Nisha Bansal
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

4.  Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction.

Authors:  Matthew D Solomon; Thomas K Leong; Eleanor Levin; Jamal S Rana; Marc G Jaffe; Stephen Sidney; Sue Hee Sung; Catherine Lee; Anthony DeMaria; Alan S Go
Journal:  J Am Heart Assoc       Date:  2020-03-05       Impact factor: 5.501

5.  Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.

Authors:  Tariq Ahmad; Lars H Lund; Pooja Rao; Rohit Ghosh; Prashant Warier; Benjamin Vaccaro; Ulf Dahlström; Christopher M O'Connor; G Michael Felker; Nihar R Desai
Journal:  J Am Heart Assoc       Date:  2018-04-12       Impact factor: 5.501

6.  Timing of AKI after urgent percutaneous coronary intervention and clinical outcomes: a high-dimensional propensity score analysis.

Authors:  Alan S Go; Thida C Tan; Rishi V Parikh; Andrew P Ambrosy; Leonid V Pravoverov; Sijie Zheng; Thomas K Leong
Journal:  BMC Nephrol       Date:  2021-09-06       Impact factor: 2.388

7.  Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads.

Authors:  Jayanthi N Koneru; Paul W Jones; Eric F Hammill; Nicholas Wold; Kenneth A Ellenbogen
Journal:  J Am Heart Assoc       Date:  2018-05-10       Impact factor: 5.501

8.  Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.

Authors:  Markus Zabel; Christian Sticherling; Rik Willems; Andrzej Lubinski; Axel Bauer; Leonard Bergau; Frieder Braunschweig; Josep Brugada; Sandro Brusich; David Conen; Iwona Cygankiewicz; Panagiota Flevari; Milos Taborsky; Jim Hansen; Gerd Hasenfuß; Robert Hatala; Heikki V Huikuri; Svetoslav Iovev; Stefan Kääb; Gabriela Kaliska; Jaroslaw D Kasprzak; Lars Lüthje; Marek Malik; Tomas Novotny; Nikola Pavlović; Georg Schmidt; Tchavdar Shalganov; Rajeeva Sritharan; Simon Schlögl; Janko Szavits Nossan; Vassil Traykov; Anton E Tuinenburg; Vasil Velchev; Marc A Vos; Stefan N Willich; Tim Friede; Jesper Hastrup Svendsen; Béla Merkely
Journal:  ESC Heart Fail       Date:  2018-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.